Navigation Links
OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
Date:5/30/2009

primarily target tissue clusterin levels with serum levels as an indicator of biological effect. - Higher incidence of stable disease (20 patients in OGX-011 plus docetaxel arm versus 12 patients in docetaxel arm) with lower incidence of disease progression as best response (1 patient in OGX- 011 plus docetaxel arm versus 4 patients in docetaxel arm) occurred in patients with measurable disease who were treated with OGX-011 plus docetaxel compared to the docetaxel arm; although, the incidence of overall response was comparable.

OGX-011 treatment was well tolerated in combination with docetaxel. There was an increase in incidence of mild fever, chills and creatinine levels (a laboratory measure for reduced kidney function) and a moderate to significant decrease in circulating lymphocytes in the blood (another laboratory measure) without any increase in infection rate compared to the docetaxel arm. The investigators concluded that the combination was well tolerated.

Brent Blumenstein, an independent statistician who conducted additional sensitivity analyses of the results, found that the survival benefit in the OGX-011 arm to be robust and not dependent on clinical trial sites or baseline characteristics of the patients.

"There is a clear separation of the survival curves," said Blumenstein. "A hazard ratio of 0.61 indicates a distinct difference in survival rates and fully justifies further Phase 3 trials. It is rare for a new intervention at this stage of development to have such strong data from a randomized clinical trial."

Cormack added, "These data clearly justify advancing to Phase 3 development, and we expect these data will be key in our partnering discussions for future clinical development and potential commercialization."

The trial was supported by funding from the Canadian Cancer Society and was conducted by the NCIC Clinical Trials
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
2. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
3. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
4. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
5. OncoGenex Reports First Quarter Financial Results
6. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
7. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
8. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
9. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
10. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
11. OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... 2014 Berkshire Corporation, the world ... announce the release of the ValuSeal® IonX™ cleanroom ... contamination containment in critical processing applications. , Recommended ... cleanroom environments, ValuSeal® IonX™ is a laser sealed ... that continues Berkshire’s innovative focus on meeting new ...
(Date:10/25/2014)... LONDON , October 24, 2014 ... CytRx Corporation (NASDAQ: CYTR ), Vertex Pharmaceuticals ... (NASDAQ: ALXN ), Peregrine Pharmaceuticals Inc. (NASDAQ: ... Free research on these five companies can be accessed ... on Thursday, October 23, 2014, ended on a positive ...
(Date:10/22/2014)... , Oct. 22, 2014 Research ... the "Global DNA Diagnostics Market (Product types, ... Share, Global Trends, Company Profiles, Demand, Insights, Analysis, ... 2020" report to their offering. ... (products, applications, techniques, end users and Geography) Global ...
(Date:10/22/2014)... Shimadzu Scientific Instruments introduces its Open Solution ... pain management and clinical markets. The software increases the ... allowing users to highlight and review results that are ... analysts to filter results by group or based on ... the need to sift through analytes of no interest. ...
Breaking Biology Technology:Ions Are Bygones, Berkshire Announces the Release of New Innovative Cleanroom Wipers 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 2Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 3Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 4Biotech Stocks Technical Data - CytRx, Vertex Pharma, Alexion Pharma, Peregrine Pharma, and StemCells 5Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 2Global DNA Diagnostics Market (Product types, Application, Technology, End User and Geography) - Forecast to 2020 3Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2
... 2011 Neogen Corporation (Nasdaq: NEOG ) announced ... 2012, which ended Aug. 31, increased 6.5% to $45,697,000, from ... year,s revenue increase is almost entirely comprised of products available ... net income increased 3.1% from the prior year to $6,004,000, ...
... N.C. -- Copper nanowires may be coming to a little ... to drive down the costs of displaying information on cell ... build foldable electronics and improved solar cells, according to new ... have developed a technique to organize copper atoms in water ...
... ANNAPOLIS, Md., Sept. 26, 2011 PharmAthene, Inc. (NYSE ... medical countermeasures against biological and chemical threats, today announced ... Board of Directors, effective September 22, 2011. ... President and Chief Executive Officer for Nycomed U.S. which will be ...
Cached Biology Technology:Neogen Reports First Quarter Revenue and Net Income Increases 2Neogen Reports First Quarter Revenue and Net Income Increases 3Neogen Reports First Quarter Revenue and Net Income Increases 4Neogen Reports First Quarter Revenue and Net Income Increases 5Copper film could lower touch screen, led and solar cell costs 2PharmAthene Appoints Brian A. Markison to the Company's Board of Directors 2PharmAthene Appoints Brian A. Markison to the Company's Board of Directors 3
(Date:10/18/2014)... 2014 Psychological stress and stress-related psychiatric disorders are ... but the molecular mechanisms underlying this relation ... to the development of targeted preventive strategies ... devastating diseases. This work is presented at ... Berlin., Now an international group of researchers ...
(Date:10/17/2014)... shown for the first time how bacteria can grow ... them the opportunity to get tremendous insights into bacteria ... also discovered the bacterial growth in chronic lung infections ... down by the immune cells. The researchers discovered the ... the bacteria, forcing the bacteria to switch to a ...
(Date:10/16/2014)... challenged conventional thinking on how the bowel lining develops ... how bowel cancer starts. , The researchers produced evidence ... the ,crypts, that are a feature of the bowel ... bowel cancer development, a controversial finding as scientists are ... 3D imaging technologies, Dr Chin Wee Tan and Professor ...
Breaking Biology News(10 mins):Researchers find why depression and aging linked to increased disease risk 2Scientists opens black box on bacterial growth in cystic fibrosis lung infection 2Cryptic clues drive new theory of bowel cancer development 2
... and misunderstandings frequently arise between individuals from different cultures. ... restrictive and another less so? A new international ... by the National Science Foundation,s Division of Behavioral and ... cultural differences and bridge the gaps between them. ...
... cause neurodegenerative prion diseases may require a genetic key, ... Chicago distinguished professor of biological sciences Susan Liebman. ... form. One prion in mammals promotes progressive neurodegenerative disorders ... how this process happens remains an open question for ...
... Calif., May 26, 2011 Epitomics, Inc. announced today ... Schering Pharma AG, Germany (Bayer HealthCare). Epitomics will use ... for Bayer HealthCare,s drug target identification and validation. ... Bayer HealthCare. This new agreement is a major expansion ...
Cached Biology News:World-wide assessment determines differences in cultures 2World-wide assessment determines differences in cultures 3Study finds 2 gene classes linked to new prion formation 2
... Molecular Imaging Systems group announces the ... Digital Imaging Systems, featuring high resolution ... fluorescence, luminescence, radiographic and chromogenic imaging ... CCD and 10x optical zoom lens ...
Compound(s) tested through a broad panel of 38 ligand binding and enzyme assays targeting the Central Nervous System. Used to determine selectivity and potential GI liabilities of compounds....
... for the extraction of unwanted detergent ... macromolecules, Applications: ,Reducing octyl glucoside concentration ... of pure β-adrenergic receptor and pure ... in 6 M urea/0.05 mM Tris ...
... Proteolytic degradation is critical to ... short-lived and regulatory proteins as important ... cellular metabolism, heat shock and stress ... surface receptors and ion channels, cell ...
Biology Products: